^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SGN-CD70A

    i
    Other names: SGN-CD70A, SGN 70A
    Company:
    Pfizer
    Drug class:
    DNA replication inhibitor, CD70-targeted antibody-drug conjugate
    Related drugs:
    almost3years
    Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. (PubMed, Blood Adv)
    Most importantly, multiple-dosing of SGN-CD70A induced complete eradication of established tumors in PDXs measured by cfDNA. Our results demonstrated marked anti-tumor activity of SGN-CD70A in CTCL PDXs, providing compelling support for its clinical investigation.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CD70 (CD70 Molecule)
    |
    CD70 expression
    |
    SGN-CD70A
    over3years
    [VIRTUAL] A CD70 antibody-drug conjugate is highly active and induces long term remission in patient-derived xenograft mouse models of cutaneous T cell lymphoma (AACR 2021)
    One week after tumor inoculation, mice were treated intraperitoneally with single-dosing of PBS, 100 μg/kg (SGN70A100) or 300 μg/kg (SGN70A300) of SGN-CD70A. Using CTCL PDX models, SGN-CD70A has marked anti-tumor activity, leading to long-term survival of treated mice. Our results provide a rationale for clinical investigation of SGN-CD70A in patients with TCL.
    Preclinical
    |
    CD70 (CD70 Molecule)
    |
    CD70 expression
    |
    SGN-CD70A • vorsetuzumab (SGN70)
    almost5years
    A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. (PubMed, Invest New Drugs)
    SGN-CD70A exposures were approximately dose proportional, with a mean terminal half-life of 3 to 5 days. Conclusions While modest single-agent activity was observed in heavily pretreated NHL patients, the applicability of SGN-CD70A is limited by the frequency and severity of thrombocytopenia, despite the long-term response with limited drug exposure.
    Clinical • P1 data • Journal
    |
    CD70 (CD70 Molecule)
    |
    SGN-CD70A